Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [2]
- Flow cytometry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-15730 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- SLC22A1 Monoclonal Antibody (2C5)
- Antibody type
- Monoclonal
- Antigen
- Purifed from natural sources
- Description
- MA5-15730 targets SLC22A1 in indirect ELISA, FACS and WB applications and shows reactivity with Human samples. The MA5-15730 immunogen is purified recombinant fragment of human SLC22A1 expressed in E. Coli. MA5-15730 detects SLC22A1 which has a predicted molecular weight of approximately 61.2kDa.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 2C5
- Vial size
- 100 µL
- Concentration
- Conc. Not Determined
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Divergent Regulation of OCT and MATE Drug Transporters by Cadmium Exposure.
A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells.
Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2.
Yang H, Zhou S, Guo D, Obianom ON, Li Q, Shu Y
Pharmaceutics 2021 Apr 13;13(4)
Pharmaceutics 2021 Apr 13;13(4)
A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells.
Chow JPH, Cai Y, Chow DTL, Chung SHK, Chau KC, Ng KY, Leung OM, Wong RMH, Law AWL, Leung YO, Kwok SY, Leung YC
PloS one 2020;15(4):e0231633
PloS one 2020;15(4):e0231633
Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2.
Obianom ON, Coutinho AL, Yang W, Yang H, Xue F, Shu Y
Molecular pharmaceutics 2017 Aug 7;14(8):2726-2739
Molecular pharmaceutics 2017 Aug 7;14(8):2726-2739
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of SLC22A1 using SLC22A1 monoclonal antibody (Product # MA5-15730) in HEK293 (1) and SLC22A1 (AA: 284-347) human IgG Fc transfected HEK293 (2) cell lysate.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of SLC22A1 using SLC22A1 monoclonal antibody (Product # MA5-15730) in HEK293 (1) and SLC22A1 (AA: 284-347) human IgG Fc transfected HEK293 (2) cell lysate.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometric analysis of Jurkat cells using SLC22A1 monoclonal antibody (Product # MA5-15730) (green) and negative control (purple).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 4 Expression of ASS1 in various cell lines and the effect of NEI-01 on their cell viability. (A) Expression of ASS1, ASL and OTC in SMMC7721, MIA PaCa-2 and PANC-1. Unperturbed asynchronously growing cells were harvested by trypsinization. After cell lysis, total cell lysates were subject to immunoblotting with anti-ASS1, anti-ASL, anti-OTC or anti-ACTIN antibodies. (B) Inhibition of cell growth of MIA PaCa-2 and PANC-1 cells but not SMMC7721 cells by NEI-01 treatment. SMMC7721 cells, MIA PaCa-2 cells or PANC-1 were seeded in 96 well-plate with ~3000 cells/well density 24 hr prior to NEI-01 treatments. After 72 hr, cells were subject to MTT assay. The relative cell viability in % vs the NEI-01 concentration was shown as mean +- SD of triplicate wells. (C) Activation of autophagic pathway upon NEI-01 treatment. MIA PaCa-2 cells were treated with indicated amount of NEI-01 for 3 or 7 days. The cells were then harvested and subject to immunoblotting using designated antibodies.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 6 Expression of ASS1 upon long-term NEI-01 treatment. ( A) Re-expression of ASS1 in NEI-01 treated MIA-PaCa-2 cells. MIA-PaCa-2 cells were propagated in DMEM supplemented with 0.01 mug/ml of NEI-01. Cells were harvested at indicated time points and subject to immunoblotting using anti-ASS1 and anti-ACTIN antibodies. Unperturbed asynchronously growing SMMC7721 cells were used as a control. (B) Reduction of ASS1 expression in NEI-01-adapted MIA PaCa-2 cells after removing of NEI-01 in the medium. MIA PaCa-2 cells adapted to NEI-01 from (A) were washed with PBS and grown in DMEM without NEI-01. The cells were harvested at indicated time points and subject to immunoblotting using anti-ASS1 and anti-ACTIN antibodies. (C) Resensitizing NEI-01-adapted cells to NEI-01. NEI-01-adapted MIA PaCa-2 cells from (A) and grown in medium without NEI-01 for 96 hr from (B) were seeded in 96 well-plate with ~3000 cells/well density 24 hr prior to NEI-01 treatments. After 72 hr, cells were subject to MTT assay. The relative cell viability in % vs the NEI-01 concentration was shown as mean +- SD of triplicate wells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Cd 2+ exposure increases membrane expression of hOCT1 and hOCT2 but not hMATE1. ( a ) Immunoblotting (IB) analysis of total and membrane fraction of hOCT2 in HEK-hOCT2 cells with and without exposure to different concentrations of Cd 2+ for 20 min. ( b ) IB analysis of total and membrane fraction of hOCT1 in HEK-hOCT1 cells with and without exposure to Cd 2+ for 20 min. ( c ) IB analysis of total and membrane fraction of hMATE1 in HEK-hMATE1 cells with and without exposure to different concentrations of Cd 2+ for 20 min. All figures are representatives of three independent experiments. Pan-cadherin and Na + /K + ATPase are served as the positive control and beta-actin as negative control for membrane proteins.